Regeneron Pharmaceuticals Stock News

Regeneron (REGN) is expected to maintain momentum on the back of a solid and diverse portfolio. The promising pipeline also sets the stage for further growth.

Regeneron (REGN) sBLA seeking label expansion of Libtayo in combination with chemotherapy as first-line treatment in advanced lung cancer accepted by the FDA.

The U.S. Food and Drug Administration ((FDA)) accepted to review Regeneron Pharmaceuticals <> and Sanofi''s <> application seeking approval of Libtayo (cemiplimab-rwlc)…

NEW YORK , Jan. 19, 2022 /PRNewswire/ -- The number of people infected by the Omicron variant of COVID-19 has broken records since the new year had started. As a result of the new wave, testing kits are in short supply. According to Anthony S. Fauci , Chief Medical Adviser to President Biden, it is going to be very important "that we get a greater capability of testing, particularly when the demand for testing is so high, with the combination of the Omicron variant itself, as well as the holiday season, where people want to get that extra level of assuredness that they''re protected, even if you are vaccinated and boosted." This week, the government responded by launching a website where Americans can request a free, at-home COVID-19 test. Todos Medical Ltd. (OTC: TOMDF ), Moderna, Inc. (NASDAQ: MRNA ), Pfizer Inc. (NYSE: PFE ), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Vaxart, Inc. (NASDAQ: VXRT ) In the meantime, in New York , which is once again the epicenter of the pandemic in the U.S., it was announced that city officials are negotiating a temporary return to remote learning for tens of thousands of students who aren''t showing up for class. "The real analysis that shows we were on the right path.

A second phase 3 trial of Sanofi (SNY) and Regeneron Pharmaceuticals'' (REGN) medicine Dupixent (dupilumab) met its main and key secondary goals, showing the drug significantly reduced…

Regeneron (REGN), Vertex Pharmaceuticals (VRTX) and BioNTech (BNTX) are three large biotech stocks that are worth betting on in the current scenario.

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have announced data from the second Phase 3 trial of Dupixent (dupilumab) in adults with uncontrolled prurigo nodularis, a

Regeneron Announces FDA Accepts For Review Libtayo In Combination With Chemotherapy For First-Line Treatment Of Advanced NSCLC © 2022 Benzinga.com. Benzinga does not provide investment advice.

CommScope (COMM), Microchip (MCHP), Regeneron (REGN), Bunge (BG) and Hologic (HOLX) are some of the stocks with high ROE to profit as Q4 earnings witness shaky start to the season.

Both companies are involved in the fight against COVID-19.

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

It can help investors spot a risky stock.

Regeneron Pharmaceuticals <> expects preliminary U.S. net product sales for EYLEA (aflibercept) Injection of ~$1.54B for Q4 and ~$5.79B for FY 2021.U.S

Regeneron Pharmaceuticals, Inc. (REGN) CEO Len Schleifer Presents at 40th Annual JPMorgan Virtual Healthcare Conference (Transcript)